VERAXA Biotech Advances FDA-Aligned Methods to Cut Animal Testing in Cancer Drug Development

VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

LOS ANGELES, CA - October 7, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration “FDA”-aligned New Approach Methodologies “NAMs” across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and sig…

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing  - News Direct

Austin, Texas, United States, 7th October 2026, NewsDirect

VERAXA Biotech Advances FDA-Aligned Methods to Cut Animal Testing in Cancer Drug Development

VERAXA Biotech is implementing FDA-aligned New Approach Methodologies to reduce animal testing in preclinical research, potentially accelerating clinical advancement and lowering costs for its antibody-based cancer therapies. The post VERAXA Biotech Advances FDA-Aligned Methods to Cut Animal Testing in Cancer Drug Development appeared first on citybuzz.